SCHEMBL5467175

SCHEMBL5467175

O=C(OCc1ccccc1)N1C[C@@H]2COC(c3ccccc3)O[C@H]2[C@H](OCc2ccccc2)C1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KLK7 P49862 3/20 0.43
KLK5 Q9Y337 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.42
MEN1 O00255 1/20 0.42
KMT2A Q03164 1/20 0.42
NPSR1 Q6W5P4 1/20 0.42
SMN1; SMN2 Q16637 3/20 0.41
NPC1 O15118 2/20 0.41
RAB9A P51151 2/20 0.41
CYP2C19 P33261 1/20 0.40
F13A1 P00488 1/20 0.39
TGM2 P21980 1/20 0.39
TGM1 P22735 1/20 0.39
BCHE P06276 1/20 0.39
HCRTR2 O43614 1/20 0.39
KDM1A O60341 1/20 0.37
PDE4B Q07343 1/20 0.36
HTR2C P28335 1/20 0.36
USP30 Q70CQ3 1/20 0.36
KCNK3 O14649 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL438380 0.91 L3MBTL1 (0.44) KLK7KLK5L3MBTL1MEN1KMT2A
SCHEMBL404245 0.76 L3MBTL1 (0.42) KLK7KLK5L3MBTL1MEN1KMT2A
SCHEMBL7720184 0.75 BCHE (0.49) KLK7KLK5L3MBTL1MEN1KMT2A
SCHEMBL1189222 0.75 MEN1 (0.62) L3MBTL1MEN1KMT2ANPSR1SMN1; SMN2
SCHEMBL18689878 0.75 BCHE (0.49) KLK7KLK5L3MBTL1MEN1KMT2A
SCHEMBL31459861 0.74 MEN1 (0.55) L3MBTL1MEN1KMT2ANPSR1SMN1; SMN2
SCHEMBL8795737 0.73 L3MBTL1 (0.42) KLK7KLK5L3MBTL1MEN1KMT2A
SCHEMBL9077430 0.72 PREP (0.41) KLK7KLK5L3MBTL1MEN1KMT2A
SCHEMBL8796249 0.72 PREP (0.41) KLK7KLK5L3MBTL1MEN1KMT2A
SCHEMBL12836007 0.72 SMN1; SMN2 (0.60) L3MBTL1MEN1KMT2ANPSR1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070270354-A1 Azasugar derivatives, heparanase inhibitors, method for preparing same, compositions containing same, use thereof SANOFI-AVENTIS (FR) 2007-11-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070270354-A1 Azasugar derivatives, heparanase inhibitors, method for preparing same, compositions containing same, use thereof HPSE, HAAO, HEXD KLK7 1402/4885KLK5 1250/4885L3MBTL1 4789/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.